For the Inventor, By the Inventor

Enter assignee name

Aventis Pharma S.a.

Calculating rank

USPTO Granted Patents = 377

% Expired Patents = 42.2

CIPO Patents = 13

EPO Patents = 69

Trademarks = 8

Forward Citations = 2,673

Loading Chart...

Loading Chart...

601 inventors (with patents filed for the assignee):

Serge Mignani (29 out of 70 patents)

Eric Bacque (24 out of 31 patents)

Michel Tabart (22 out of 44 patents)

4. Jean-Christophe Carry (21 out of 45 patents)

5. Marie-Christine Bissery (18 out of 22 patents)

6. Jean Bouquerel (17 out of 22 patents)

7. Dominique Lesuisse (16 out of 24 patents)

8. Augustin Hittinger (15 out of 17 patents)

9. Baptiste Ronan (15 out of 32 patents)

10. Michel Perricaudet (14 out of 38 patents)

11. Patrick Mailliet (14 out of 23 patents)

12. Jean-Luc Malleron (14 out of 32 patents)

13. Fabrice Viviani (14 out of 22 patents)

14. Jean-Claude Barriere (14 out of 28 patents)

15. Bruno Filoche (13 out of 17 patents)

Core Competencies:

Dimethoxy Docetaxel

Cabazitaxel

Kinase Inhibitors

Cancer Treatment

Gene Mutations

Pharmaceutical Compositions

Pyrazolyl Derivatives

Oligosaccharides

Transgenic Animals

Heparin

Steroid Derivatives

Taxane Derivatives

377 patents: Sort by Forward Citations

1. 10160739 - Crystalline forms of dimethoxy docetaxel and methods for preparing the same (2018-12-25),

2. 9540693 - Mutations of the parkin gene, compositions, methods and uses (2017-01-10),

3. 9309210 - Crystalline form of cabazitaxel and process for preparing the same (2016-04-12),

4. 9126969 - Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof (2015-09-08),

5. 8962021 - Solid pharmaceutical composition comprising telithromycin (2015-02-24),

6. 8927592 - Antitumoral use of cabazitaxel (2015-01-06),

7. 8852878 - Method for identifying an antagonist of guanine nucleotide releasing factor 1 (2014-10-07),

8. 8846959 - Crystalline forms of dimethoxy docetaxel and methods for preparing the same (2014-09-30),

9. 8835618 - Mutations of the parkin gene (2014-09-16),

10. 8709426 - Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2014-04-29),

11. 8685705 - Desmosterol-producing yeast strains and uses thereof (2014-04-01),

12. 8642028 - Recombinant adenoviruses encoding the specific iodine transporter (NIS) (2014-02-04),

13. 8608961 - Method for affinity chromatography of antithrombin III (2013-12-17),

14. 8492610 - Transgeneic animal expressing a multiple mutated form of presenilin 1 (2013-07-23),

15. 8481589 - Taxoid-based compositions (2013-07-09),

Company Overview

Aventis Pharma S.A., headquartered in Antony, France, specializes in the development and manufacturing of innovative pharmaceutical compositions aimed at treating various forms of cancer. The company focuses on advanced therapeutic agents, including Dimethoxy Docetaxel and Cabazitaxel, along with kinase inhibitors that target specific gene mutations. With a commitment to addressing complex medical needs, Aventis Pharma leverages its expertise in pyrazolyl derivatives and oligosaccharides to enhance treatment efficacy and patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

377 Patents

#1 in Antony

#67 in France

#2,449 in the World

Aventis Pharma S.a.

Forward Citations = 2,673

601 inventors:

Serge Mignani (29 out of 70 patents)

Eric Bacque (24 out of 31 patents)

Michel Tabart (22 out of 44 patents)

4. Jean-Christophe Carry (21 out of 45 patents)

5. Marie-Christine Bissery (18 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aventis Pharma S.a.. Retrieved from https://idiyas.com/company/aventis-pharma-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…